New research suggests that electrical spinal cord stimulation could improve muscle function for patients who have spinal ...

The Muscular Dystrophy Association celebrates the FDA approval of Evrysdi in tablet form, a more accessible treatment option ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited ... complementing existing neuroprotective ...

Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy: Basel Friday, February 14, 2025, 13:00 Hrs [IST] Roche, announced that the US Food ...

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...

leading to muscle weakness and atrophy. In recent years, advancements in medical science have led to the development of innovative treatments for SMA, offering hope to patients and caregivers. This ...

SMA is a genetic disorder of movement (wasting) because the muscles aren ... Spinal Muscular Atrophy (SMA) is a significant, life-changing condition, yet advancements in treatment and early ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Now, he's down to the use of just one thumb and his mouth, but those muscles are slowly getting weaker. There is no cure for spinal muscular atrophy, but treatments can stop its progression and ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).